Healthcare / BiotechnologyNasdaqCM
$4.84
-0.07 (-1.43%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-14.8M · quality 48.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$225M
P/E
N/A
•EV/EBITDA
N/A
•ROE
208.5%
↑Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2013–2025 · 12 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.05x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-293.4M · FCF $-13.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||
| Revenue | — | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — |
| Net Income | $-293.4M | $-293.4M | $1.4M | $-30.0M | $-32.1M | $-49.9M | $1.9M | $-72.2M | $-50.2M | $-31.5M | $-31.0M | $-27.1M | $-56.9M | $-3.3M |
| EBITDA | $-293.4M | $-293.4M | $6.0M | $-21.7M | $-24.7M | — | $1.9M | $-75.8M | $-51.7M | $-41.2M | $-30.2M | $-26.1M | $-54.8M | — |
| EPS | -34.67 | -34.67 | 0.19 | -4.61 | -6.01 | -9.35 | 0.40 | -14.80 | — | — | — | — | — | — |
| Balance Sheet | ||||||||||||||
| Current Ratio | 17.65 | 17.65 | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||
| Free Cash Flow | $-13.5M | $-13.5M | $-19.6M | $-14.8M | $-24.7M | — | — | — | — | $3.0M | — | — | — | — |
| Returns | ||||||||||||||
| ROE | 208.5% | 208.5% | -5.6% | 105.4% | 160.3% | -625.7% | 3.7% | -259.8% | -55.6% | -24.0% | -29.3% | -49.0% | -110.5% | -16.2% |
| Valuation | ||||||||||||||
| P/E | — | — | 12.00 | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | — | — | -0.68 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||
| EPS Growth | -18347.4% | -18347.4% | 104.1% | 23.3% | — | -2437.5% | 102.7% | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+214.3%
Start / end P/E
n/dx → n/dx
EPS bridge
0.19 → -34.67
Residual
+214.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.